Fresenius SE KGaA Management

How has Michael Sen's remuneration changed compared to Fresenius SE KGaA's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	€312m
Dec 31 2023	€7m	€2m	€353m
Sep 30 2023	n/a	n/a	€941m
Jun 30 2023	n/a	n/a	€1b
Mar 31 2023	n/a	n/a	€1b
Dec 31 2022	€5m	€1m	€1b
Sep 30 2022	n/a	n/a	€1b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	€2m	€755k	€2b

Compensation vs Market: Michael's total compensation ($USD7.57M) is above average for companies of similar size in the German market ($USD5.06M).

Compensation vs Earnings: Michael's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Michael Sen (56 yo)

3.3yrs

Tenure

€6,992,000

Compensation

Mr. Michael Sen is Chairman of the Supervisory Board at Fresenius Medical Care AG from July 14, 2023. He is Chief Executive Officer & President of Fresenius Management SE at Fresenius SE & Co. KGaA since O...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Sen	CEO, President & Chairman of Management Board of Fresenius Management SE	3.3yrs	€6.99m	no data
Sara Hennicken	CFO & Member of the Management Board - Fresenius Management SE	1.8yrs	€2.39m	no data
Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	1.3yrs	€3.12m	no data
Michael Moser	Member of Management Board of Fresenius Management SE	less than a year	€1.62m	no data
Robert Moller	Member of the Management Board of Fresenius Management SE	less than a year	€1.42m	no data
Markus Georgi	Senior Vice President of Investor Relations	9.3yrs	no data	no data
Matthias Link	Senior Vice President Corporate Communications	no data	no data	no data

1.6yrs

Average Tenure

49.5yo

Average Age

Experienced Management: FRE's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Gerd Krick	Honorary Chairman of Supervisory Board	3.2yrs	€219.00k	no data
Michael Diekmann	Independent Deputy Chairman of the Supervisory Board	9.2yrs	€320.00k	no data
Wolfgang Kirsch	Independent Chairman of Supervisory Board	4.5yrs	€560.00k	no data
Konrad Kölbl	Independent Member of Supervisory Board	17yrs	€185.00k	no data
Grit Genster	Independent Deputy Chairperson of the Supervisory Board	4.2yrs	€310.00k	no data
D. Albrecht	Independent Member of Supervisory Board	13.5yrs	€180.00k	no data
Iris Loew-Friedrich	Independent Member of Supervisory Board	8.2yrs	€180.00k	no data
Susanne Zeidler	Independent Member of the Supervisory Board	3.2yrs	€290.00k	no data
Frauke Lehmann	Independent Member of Supervisory Board	8.2yrs	€180.00k	no data
Oscar De Paco	Independent Member of Supervisory Board	8.2yrs	€180.00k	no data
Bernd Behlert	Independent Member of Supervisory Board	5.8yrs	€215.00k	no data
Christoph Zindel	Independent Member of Supervisory Board	2.2yrs	€220.00k	no data

7.0yrs

Average Tenure

64.5yo

Average Age

Experienced Board: FRE's board of directors are considered experienced (7 years average tenure).

Fresenius SE KGaA Management

Management criteria checks 1/4

Key information

Recent management updates

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Recent updates

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Price target decreased to €40.39

Second quarter 2022 earnings: EPS misses analyst expectations

Healius Reportedly Launches Day Surgery Sale Process

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Upcoming dividend of €0.92 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?